| Trial ID: | L7100 |
| Source ID: | NCT02890745
|
| Associated Drug: |
Empagliflozin
|
| Title: |
The Effect Effect of Empagliflozin on Oxidative Stress in Patients With Type 2 Diabetes
|
| Acronym: |
EMPOX
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: Empagliflozin|DRUG: Placebo
|
| Outcome Measures: |
Primary: Urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine (nmol/24h), Change from baseline after fourteen days of intervention|Urinary excretion of 8-oxo-7,8-dihydroguanosine (nmol/24h), Change from baseline after fourteen days of intervention | Secondary: Plasma levels of malondialdehyde, Change from baseline after fourteen days of intervention|Plasma levels of iron, ferritin, transferrin and transferrin saturation, Measured at baseline and after intervention
|
| Sponsor/Collaborators: |
Sponsor: Henrik Enghusen Poulsen | Collaborators: University Hospital, Gentofte, Copenhagen|University of Copenhagen
|
| Gender: |
MALE
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
31
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2016-11
|
| Completion Date: |
2020-01-22
|
| Results First Posted: |
|
| Last Update Posted: |
2021-06-10
|
| Locations: |
Center for Diabetes Research, Gentofte Hospital, Hellerup, 2900, Denmark
|
| URL: |
https://clinicaltrials.gov/show/NCT02890745
|
